Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AZSTARYS vs ADDERALL 20
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
AZSTARYS is a prodrug of dexmethylphenidate, a central nervous system stimulant. The exact mechanism of action in attention deficit hyperactivity disorder (ADHD) is unknown, but it is thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron, increasing their levels in the extraneuronal space.
Adderall 20 is a combination of amphetamine and dextroamphetamine, which are central nervous system stimulants. They increase the levels of norepinephrine and dopamine in synaptic clefts by inhibiting their reuptake and promoting their release from presynaptic neurons.
Treatment of attention deficit hyperactivity disorder (ADHD) in patients aged 6 years and older
Attention Deficit Hyperactivity Disorder (ADHD),Narcolepsy,Off-label: Treatment-resistant depression, obesity, cognitive enhancement
Initial: 39.2 mg oral once daily in the morning; titrate weekly by 19.6 mg increments as needed; maximum dose: 78.4 mg once daily.
Initial: 5 mg orally once or twice daily; may increase by 5 mg increments at weekly intervals. Usual effective dose: 20-40 mg/day divided into 1-2 doses. Maximum: 40 mg/day (immediate-release); 60 mg/day (extended-release).
Serdexmethylphenidate: 1.5 hours; dexmethylphenidate: 3.5 hours. The terminal half-life of total dexmethylphenidate after AZSTARYS is approximately 6.5 hours, supporting once-daily dosing.
d-Amphetamine: 10-13h; l-Amphetamine: 13-16h. Clinical steady-state reached in 2-3 days.
AZSTARYS is a prodrug that is converted to dexmethylphenidate primarily through enzymatic hydrolysis by carboxylesterase 1 (CES1). The active metabolite dexmethylphenidate is further metabolized primarily via deesterification to ritalinic acid, with minor hydroxylation pathways.
Primarily hepatic via CYP2D6 and, to a lesser extent, CYP2C19, CYP3A4, and CYP2C9. Metabolites include 4-hydroxyamphetamine, alpha-hydroxyamphetamine, and norephedrine.
Renal: 90% (primarily as metabolites, with 50-70% as the major metabolite (-)-phensuximide glucuronide). Fecal: <5%.
Renal: ~90% unchanged; ~10% as deaminated metabolites; fecal <5%.
Serdexmethylphenidate: 94% (bound to albumin); dexmethylphenidate: 15-20%.
16% (primarily albumin).
Serdexmethylphenidate: 5.6 L/kg; dexmethylphenidate: 2.7 L/kg. High Vd indicates extensive tissue distribution.
3.2-5.6 L/kg; indicates extensive tissue distribution.
Oral: 100% for serdexmethylphenidate (prodrug); dexmethylphenidate from the prodrug is 87% bioavailable relative to equivalent dexmethylphenidate dose.
Oral IR: ~90%; ER: ~90%.
e GFR 15-29 m L/min: not recommended; e GFR <15 m L/min: contraindicated. No dose adjustment for e GFR >=30 m L/min.
e GFR 15-29 m L/min: 50% of usual dose. e GFR < 15 m L/min: avoid use due to accumulation risk. Hemodialysis: not recommended.
Child-Pugh A: no dose adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: not recommended.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 50%. Child-Pugh Class C: avoid use.
Age 6-12 years: initial 19.6 mg oral once daily; titrate weekly by 19.6 mg; max 78.4 mg. Age 13-17 years: same as adult dosing.
Children 3-5 years: 2.5 mg orally once daily; increase by 2.5 mg weekly. Children 6 years and older: 5 mg once or twice daily; increase by 5 mg weekly. Maximum dose: 40 mg/day (immediate-release). Weight-based: 0.3-1.5 mg/kg/day (immediate-release).
No specific studies in elderly; initiate at low end of dosing range due to increased sensitivity to sympathomimetics. Monitor cardiovascular status.
Initial: 2.5 mg once or twice daily; increase slowly by 2.5 mg increments at weekly intervals. Use lowest effective dose due to increased sensitivity and risk of cardiovascular adverse effects.
AZSTARYS has a high potential for abuse and misuse, which can lead to dependence. Misuse may cause sudden death or serious cardiovascular adverse events.
Abuse and dependence: Amphetamines have a high potential for abuse, which can lead to dependence and serious cardiovascular events. Misuse may cause sudden death or serious cardiovascular adverse events.
Serious cardiovascular events: Sudden death, stroke, and myocardial infarction have been reported in patients with structural cardiac abnormalities or other serious heart problems.,Blood pressure and heart rate increase: Monitor closely for tachycardia and hypertension.,Psychiatric adverse events: May precipitate psychotic or manic symptoms in patients with no prior history, or exacerbate symptoms in those with pre-existing psychiatric disorders.,Priapism: Prolonged and painful erections may occur, requiring immediate medical attention.,Peripheral vasculopathy: Including Raynaud's phenomenon, monitor for digital changes.,Long-term suppression of growth: Monitor growth in pediatric patients during treatment.
Cardiovascular: Serious cardiovascular events including sudden death in patients with pre-existing structural cardiac abnormalities.,Psychiatric: Exacerbation of pre-existing psychosis, mania, or aggression; new-onset psychosis or mania.,Growth suppression: Long-term use in children may suppress growth.,Seizures: May lower seizure threshold in patients with seizure disorders.,Serotonin syndrome: Risk when used with other serotonergic drugs.,Peripheral vasculopathy: Including Raynaud's phenomenon.
Hypersensitivity to methylphenidate products or any component of AZSTARYS,Concurrent treatment with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing an MAOI,Glaucoma,Tics or family history of Tourette's syndrome,Severe anxiety, tension, or agitation
Hypersensitivity to amphetamine or any component of the formulation,Advanced arteriosclerosis,Symptomatic cardiovascular disease,Moderate to severe hypertension,Hyperthyroidism,Glaucoma,Agitated states,History of drug abuse,Concurrent use or within 14 days of MAO inhibitors (risk of hypertensive crisis)
High-fat meals delay time to peak concentration (Tmax) by approximately 2 hours but do not affect overall exposure (AUC). Avoid alcohol as it may alter drug release characteristics. No specific food restrictions; can be taken with or without food.
High-fat meals can delay absorption of Adderall. Acidic foods (e.g., citrus fruits, juices) and vitamin C may decrease absorption; avoid within 1 hour of dosing. Caffeine and other stimulants may increase side effects. Alcohol should be avoided. Grapefruit juice may increase amphetamine levels, so limit or avoid.
Pregnancy Category C. First trimester: Animal studies show increased risk of fetal malformations (e.g., cardiac, skeletal). Second/third trimester: Potential for preterm delivery, low birth weight, and neonatal withdrawal symptoms (e.g., irritability, feeding difficulties) due to chronic exposure.
First trimester: Increased risk of premature delivery and low birth weight; possible association with cardiovascular malformations (limited data). Second/third trimester: Risk of fetal growth restriction, preterm birth, neonatal withdrawal syndrome (irritability, poor feeding), and persistent pulmonary hypertension. Chronic use may impair fetal development.
Excreted in human milk; M/P ratio not established. Limited data suggest potential for adverse effects in nursing infants (e.g., irritability, poor feeding). Decision to breastfeed should weigh risks and benefits; consider alternative feeding if drug is essential.
Excreted into breast milk; M/P ratio approximately 2.5–7.5. Relative infant dose estimated at 5–14% of maternal weight-adjusted dose. Potential for decreased appetite, insomnia, and growth suppression in breastfed infants. American Academy of Pediatrics recommends use only if benefit outweighs risk, with close monitoring.
No established dose adjustments in pregnancy; however, increased clearance may reduce efficacy. Titrate to lowest effective dose. Consider alternative therapies if possible due to unknown risks.
Due to increased renal clearance and expanded plasma volume, total amphetamine exposure may decrease, potentially requiring dose increase (monitor clinical response). However, insufficient data to recommend fixed adjustments; individualize based on symptom control and tolerability.
AZSTARYS (serdexmethylphenidate and dexmethylphenidate) is a prodrug combination with immediate-release and delayed-release components. Onset of action occurs within 1 hour, and duration is approximately 13 hours. It can be taken with or without food, but high-fat meals delay peak concentration. Avoid use in patients with pre-existing cardiovascular disease, hypertension, hyperthyroidism, glaucoma, or history of drug abuse. Monitor for growth suppression in children, weight loss, and insomnia. Avoid concomitant use with MAOIs or within 14 days of discontinuation. May exacerbate tics or Tourette syndrome. Use with caution in patients with seizure disorder or those taking CYP2D6 inhibitors (e.g., fluoxetine, paroxetine) due to increased dexmethylphenidate exposure.
Adderall 20 mg is a mixed amphetamine salt formulation (75% dextroamphetamine, 25% levoamphetamine). Monitor for cardiovascular adverse effects; consider baseline ECG in patients with cardiac risk factors. Avoid in patients with structural cardiac abnormalities, cardiomyopathy, or arrhythmias. Use with caution in patients with hypertension, hyperthyroidism, or glaucoma. May exacerbate tics and Tourette syndrome. Administer first dose upon awakening; avoid afternoon doses due to insomnia risk. Monitor growth in children; may cause weight loss and growth suppression. Assess for potential for abuse and dependence; use lowest effective dose.
Take exactly as prescribed; do not crush or chew capsules.,Avoid alcohol while taking this medication.,Report any chest pain, shortness of breath, or palpitations immediately.,May cause dizziness or blurred vision; avoid driving until effects are known.,Use with caution in patients with history of drug dependence or abuse.,Keep out of reach of children; do not share medication.,Store at room temperature away from moisture and heat.
Take exactly as prescribed; do not crush or chew extended-release capsules.,Take early in the morning to avoid trouble sleeping.,Avoid taking with high-fat meals as it may delay absorption.,Do not drink alcohol while taking this medication.,Report any chest pain, shortness of breath, or fainting immediately.,Avoid driving or operating heavy machinery until you know how Adderall affects you.,Store at room temperature away from moisture and heat.,Keep out of reach of children and pets.,Do not share your medication with others; it is a controlled substance.,Inform your doctor if you have a history of heart disease, high blood pressure, seizures, or mental health conditions.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AZSTARYS vs ADDERALL 20, answered by our medical review team.
AZSTARYS is a CNS Stimulant that works by AZSTARYS is a prodrug of dexmethylphenidate, a central nervous system stimulant. The exact mechanism of action in attention deficit hyperactivity disorder (ADHD) is unknown, but it is thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron, increasing their levels in the extraneuronal space.. ADDERALL 20 is a CNS Stimulant that works by Adderall 20 is a combination of amphetamine and dextroamphetamine, which are central nervous system stimulants. They increase the levels of norepinephrine and dopamine in synaptic clefts by inhibiting their reuptake and promoting their release from presynaptic neurons.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AZSTARYS and ADDERALL 20 depend on the specific clinical indication. These are both CNS Stimulant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AZSTARYS is: Initial: 39.2 mg oral once daily in the morning; titrate weekly by 19.6 mg increments as needed; maximum dose: 78.4 mg once daily.. The standard adult dose of ADDERALL 20 is: Initial: 5 mg orally once or twice daily; may increase by 5 mg increments at weekly intervals. Usual effective dose: 20-40 mg/day divided into 1-2 doses. Maximum: 40 mg/day (immediate-release); 60 mg/day (extended-release).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AZSTARYS and ADDERALL 20 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AZSTARYS is classified as Category C. Pregnancy Category C. First trimester: Animal studies show increased risk of fetal malformations (e.g., cardiac, skeletal). Second/third trimester: Potential for preterm delivery, . ADDERALL 20 is classified as Category C. First trimester: Increased risk of premature delivery and low birth weight; possible association with cardiovascular malformations (limited data). Second/third trimester: Risk of f. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.